Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 12c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($0.86), $0.12 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $303.33 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings
• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS